Skip to content

NBP

NovaBridge Biosciences

NASDAQ · USHealthcareBiotechnology
$1.82+2.25%

Price as of Jul 20, 2026

NBP ownership

NovaBridge Biosciences ownership & insider activity

Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.

Insider Activity

Sentiment
90/100
Buys (3m)
1
Sells (3m)
4
Net (3m)
$511.4K
Insiders buying
Insider trades by month Buys Sells
Apr
May
Jun
Jul
Context3-month price -26.8%
DateInsiderTypeSharesPrice
Jul 10, 2026Lin Liwei Lorraineofficer: General CounselGrant254,780$1.93
Jul 10, 2026Hagler Mark Arnoldofficer: Chief Commercial OfficerGrant949,050$1.93
Jul 8, 2026Gupta Srishtidirector, officer: Chief Executive OfficerGrant3,000,000$2.01
Jul 7, 2026Xu Cong Claireofficer: SVP, Clinical DevelopmentSell4,485$0.89
Jul 7, 2026Xu Cong Claireofficer: SVP, Clinical DevelopmentOption5,405
Jul 7, 2026Xu Cong Claireofficer: SVP, Clinical DevelopmentOption12,432
Jun 30, 2026Fu WeidirectorGrant1,087,720$2.45
Jun 30, 2026Fu WeidirectorGrant1,010,100
Jun 30, 2026Fu WeidirectorGrant725,140$2.45
Jun 24, 2026Cao Sean Wuxiongdirector, officer: Chief Bus. Development OfficerGrant181,290$1.53
Jun 24, 2026Cao Sean Wuxiongdirector, officer: Chief Bus. Development OfficerGrant181,280
Jun 22, 2026Dennis Phillip Andrewofficer: Chief Medical OfficerOption10,302
Jun 22, 2026Dennis Phillip Andrewofficer: Chief Medical OfficerSell8,494$0.66
Jun 22, 2026Dennis Phillip Andrewofficer: Chief Medical OfficerOption23,695
Jun 2, 2026Xu Cong Claireofficer: SVP, Clinical DevelopmentOption4,079
Jun 2, 2026Xu Cong Claireofficer: SVP, Clinical DevelopmentSell3,494$3.94
Jun 2, 2026Xu Cong Claireofficer: SVP, Clinical DevelopmentOption9,382
May 18, 2026Cao Sean Wuxiongdirector, officer: See RemarksSell21,399$1.99
Apr 28, 2026Hagler Mark Arnoldofficer: See RemarksBuy230,000$2.51

Source: NBP SEC Form 4 filings, latest Jul 10, 2026. For informational purposes only — not investment advice.